<!DOCTYPE html>
<html>
<head>
<title>Refpages</title>
<link rel="stylesheet" href="refstyle.css">
</head>

<body>

<!-- refpage 15---------------------------------------------------------------------------------------------------------->
<div class = "title">Centrally-acting antihypertensives</div>

<div class = "source">
<div class = "quote">
Central antihypertensives  (Table 2: Fall-risk increasing drugs (FRIDs) according to the preliminary (September 2019) European consensus list.)
</div><div class = "quote">
Item 10: Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), unless clear intolerance or lack of efficacy with other classes of antihypertensives: High risk of adverse CNS effects; May cause bradycardia and orthostatic hypotension; Not recommended as routine treatment for hypertension: Consider other safer antihypertensive.
</div><div class="ref" name="7">
GheOP3S-tool draft 3 
</div>
</div>

<div class = "source">
<div class = "quote">
<strong>Centrally-acting antihypertensives</strong>
Fall-risk assessment: In which cases to consider withdrawal?
<ol>
<li>If hypotension, OH, or sedative symptoms
</li>
</ol>
Is stepwise withdrawal needed?
<ol>
<li>Consider monitoring after deprescribing
<ol>
<li>Monitor: hypertension
</li>
</ol>
(If there is) No valid indication &rarr; Consider stopping the central AH tapering the dose:depending on the half-life of the drug, can be done within days to weeks. <br>
Safer alternatives available &rarr; Change to safer alternative<br>
Lower dose has not been tried &rarr; Try lower dose<br>
Otherwise &rarr; No safer alternative is available: Perform a shared decision-making review with patient liaising with other relevant specialist as appropriate. Consider withdrawal if hypotension, orthostatic hypotension, or sedative symptoms present. Take patient goals into account. <br>
Withdrawal: After withdrawal or dose reduction monitor for 1) changes in symptoms e.g., dizziness, orthostatic hypotension, 2) fall incidents and 3) blood pressure. Organize follow-up on an individual basis taking into account patient factors including patient history, blood pressure levels and possible occurrence of withdrawal symptoms.
</div><div class="ref" name="10">
Lotta J Seppala, Mirko Petrovic, Jesper Ryg, Gulistan Bahat, Eva Topinkova, Katarzyna Szczerbinska, Tischa J M van der Cammen, Sirpa Hartikainen, Birkan Ilhan, Francesco Landi, Yvonne Morrissey, Alpana Mair, Marta Guti&eacute;rrez-Valencia, Marielle H Emmelot-Vonk, Mar&iacute;a &Aacute;ngeles Caballero Mora, Michael Denkinger, Peter Crome, Stephen H D Jackson, Andrea Correa-P&eacute;rez, Wilma Knol, George Soulis, Adalsteinn Gudmundsson, Gijsbertus Ziere, Martin Wehling, Denis O&acute;Mahony, Antonio Cherubini, Nathalie van der Velde, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs, Age and Ageing, 2020;, afaa249, https://doi.org/10.1093/ageing/afaa249
<br> Appendix IV: <a href="https://web.archive.org/web/20221104165129/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244563/bin/appendixstoppfall2020-_clean_copy_afaa249.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244563/bin/appendixstoppfall2020-_clean_copy_afaa249.pdf</a>
</div>
</div>

<div class = "source">
<div class = "quote">
Evalueer 2-4 weken na het afbouwen van het bloeddrukverlagende middel of de nieuwe behandeldoelen gehaald zijn.
</div><div class="ref" name="97">
Kennisdocument Bloeddrukverlagende middelen. NHG 2020. <a href="https://web.archive.org/web/20210305014440/https://richtlijnen.nhg.org/files/2020-11/Eindversie%20Kennisdocument%20Bloeddrukverlagende%20middelen_0.pdf">https://richtlijnen.nhg.org//files/2020-11/Eindversie%20Kennisdocument%20Bloeddrukverlagende%20middelen_0.pdf</a>
</div>
</div>

<div class = "source">
<div class = "quote">
Rebound hypertension occurs after abrupt cessation of many antihypertensive drugs.
</div><div class="ref" name="98">
Reidenberg MM. Drug Discontinuation Effects Are Part of the Pharmacology of a Drug. J Pharmacol Exp Ther. 2011 Nov; 339(2): 324â€“328. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200000/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200000/</a>
</div>
</div>

</body>
